EPISODE · Dec 8, 2025 · 9 MIN
ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed highlights the company's FLT3xCD3 bispecific T-cell engager data at ASH in AML and MDS
from BiotechTV - News · host BiotechTV
He describes how this asset binds to the extracellular domain and therefore can work for both wild type patients and those with mutations. Plus, recent regulatory news on zipalertinib and when to expect to see autoimmune data.
Embed this episode
Ready to play
ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed highlights the company's FLT3xCD3 bispecific T-cell engager data at ASH in AML and MDS
0:00
9:52
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 9 minutes long.
When was this BiotechTV - News episode published?
This episode was published on December 8, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!